1. Home
  2. AZTR vs RELI Comparison

AZTR vs RELI Comparison

Compare AZTR & RELI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AZTR
  • RELI
  • Stock Information
  • Founded
  • AZTR 2014
  • RELI 2013
  • Country
  • AZTR United States
  • RELI United States
  • Employees
  • AZTR N/A
  • RELI N/A
  • Industry
  • AZTR Biotechnology: Pharmaceutical Preparations
  • RELI Specialty Insurers
  • Sector
  • AZTR Health Care
  • RELI Finance
  • Exchange
  • AZTR Nasdaq
  • RELI Nasdaq
  • Market Cap
  • AZTR 3.7M
  • RELI 4.0M
  • IPO Year
  • AZTR 2023
  • RELI N/A
  • Fundamental
  • Price
  • AZTR $0.16
  • RELI $1.06
  • Analyst Decision
  • AZTR
  • RELI
  • Analyst Count
  • AZTR 0
  • RELI 0
  • Target Price
  • AZTR N/A
  • RELI N/A
  • AVG Volume (30 Days)
  • AZTR 1.0M
  • RELI 154.5K
  • Earning Date
  • AZTR 08-11-2025
  • RELI 07-30-2025
  • Dividend Yield
  • AZTR N/A
  • RELI N/A
  • EPS Growth
  • AZTR N/A
  • RELI N/A
  • EPS
  • AZTR N/A
  • RELI N/A
  • Revenue
  • AZTR N/A
  • RELI $14,061,478.00
  • Revenue This Year
  • AZTR N/A
  • RELI N/A
  • Revenue Next Year
  • AZTR N/A
  • RELI N/A
  • P/E Ratio
  • AZTR N/A
  • RELI N/A
  • Revenue Growth
  • AZTR N/A
  • RELI 1.07
  • 52 Week Low
  • AZTR $0.14
  • RELI $0.91
  • 52 Week High
  • AZTR $0.80
  • RELI $5.11
  • Technical
  • Relative Strength Index (RSI)
  • AZTR 33.84
  • RELI 38.40
  • Support Level
  • AZTR $0.14
  • RELI $1.02
  • Resistance Level
  • AZTR $0.16
  • RELI $1.10
  • Average True Range (ATR)
  • AZTR 0.01
  • RELI 0.08
  • MACD
  • AZTR -0.00
  • RELI 0.01
  • Stochastic Oscillator
  • AZTR 26.81
  • RELI 33.33

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About RELI Reliance Global Group Inc.

Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.

Share on Social Networks: